close read more

The agility of an integrated industrial model

PIERRE VENESQUE

Executive Vice President Industry


WHAT ARE THE STRENGTHS OF SERVIER’S INDUSTRIAL MODEL?

Our integrated model enables us to be in control of all stages of the medicine’s life cycle, from development to industrialization and distribution. With 98% of our active ingredients produced in-house for our brand-name medicines, we guarantee a consistent level of quality. Our industrial network of 16 sites around the world is another major advantage: it ensures the flexibility of our production capacities, allowing us to make use of the complementarity between the different sites in the face of varying volumes. This industrial network also guarantees the reliability of our teams’ expertise and skills.

 

WHAT ARE YOUR MAJOR INDUSTRIAL CHALLENGES?

In an ever-changing world, we are adapting our industrial model to increase agility and flexibility. Changing regulatory requirements (e.g., serialization), increased digitalization of our businesses and the reliability of raw material supplies are all factors to be taken into consideration. At the same time, our industrial model is evolving with the Group’s ongoing transformation: the rise of oncology and the arrival in our portfolio of two new medicines following the acquisition of Shire’s oncology branch, are new challenges that require us to adapt our supply chain and production management. Finally, the evolution toward increasingly customized medicine, with, for example, the development of medicines combining, in a single tablet, several molecules in several dosages, requires new production methods.

 

WHAT ARE YOUR DRIVING FORCES IN ADDRESSING THEM?

We have launched a project to transform our organization in order to be more flexible in the face of fluctuating demand. Its objectives are twofold: to secure production in order to guarantee the distribution of our medicines to patients, and to support the Group’s long-term ambition.